ClinicalTrials.gg
Not yet recruitingNCT07586150LIFETRAINUpdated May 14, 2026

Personalized Pharmaco-Lifestyle Interventions for Severe Mental Illnesses (LIFETRAIN)

An interventional study of Semaglutide (SEMA) and Exercise module in Severe Mental Illness, Depression / Major Depressive Disorder and Bipolar Disorder (BD), sponsored by Ludwig-Maximilians - University of Munich. Not yet recruiting at 5 sites in 3 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-14.

Sponsored by Ludwig-Maximilians - University of Munich · Not applicable, Interventional, and Treatment

How we know · 4 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This randomized, rater-blind, multicenter clinical trial will evaluate whether a personalized pharmaco-lifestyle intervention improves mental functioning in adults with severe mental illness, including schizophrenia, bipolar disorder, or major depressive disorder. Participants will be randomized to either a modular individualized intervention program or a structured psychoeducation control condition. The individualized intervention may include physical exercise, an anti-inflammatory diet, sleep intervention, social prescribing, semaglutide for eligible participants with overweight or obesity, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. The primary outcome is change in the SF-36 Mental Component Summary score from baseline to Month 3.

02

Conditions studied

  • Severe Mental Illness
  • Depression / Major Depressive Disorder
  • Bipolar Disorder (BD)
  • Schizophrenia
03

In context

Mental Disorders

1,746 studies on the registry are indexed under Mental Disorders; 350 are open to participants now.

This study's planned enrollment of 140 is above the median of 100 across 1,305 interventional studies indexed under Mental Disorders.

Browse Mental Disorders studies →

Lead sponsor

Ludwig-Maximilians - University of Munich is the lead sponsor of 223 studies on the registry; 29 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years
  • Able and willing to provide written
  • Diagnosis of schizophrenia, bipolar disorder, or major depressive disorder according to , confirmed by M.I.N.I.
  • Female participants of must agree to use an effective method of
  • Stable psychopathology defined as BPRS less than or equal to 41, MADRS less than or equal to 34, and YMRS less than or equal to 25, with stable psychopharmacological treatment for at least 2 weeks
  • Reduced functioning at screening defined as SF-36 score less than or equal to 40
  • If using benzodiazepines, dose less than or equal to 2 mg lorazepam equivalent per day
  • Stable somatic condition for at least 4 weeks
  • For semaglutide treatment: overweight with at least 27 and less than 30 kg/m² plus at least one weight-related risk condition, or obesity with BMI at least 30 kg/m²
  • For optional adaptive neurostimulation: MADRS score at least 19
  • Expected ability to comply with study procedures in the investigator's judgment

Exclusion criteria

Exclusion Criteria:

  • Unable to provide
  • Current or past neurological disorder or structural brain pathology that may affect study procedures
  • Known intolerance or to semaglutide
  • Pregnancy or lactation
  • Serious suicidal risk
  • Substance dependence within the last 3 months
  • less than 18.5 kg/m²
  • less than 30 mL/min/1.73 m²
  • Type 1 diabetes, diabetic ketoacidosis, diabetic retinopathy, or poorly controlled diabetes with recurrent hypoglycemic episodes
  • Pancreatitis, history of pancreatitis, or pancreatic cancer
  • Multiple endocrine neoplasia type 2 or personal/family history of medullary thyroid cancer
  • Pre-existing significant gastrointestinal conditions such as inflammatory bowel disease or gastroparesis
  • Need for acute surgery
  • Other medical condition that may affect study procedures or participant safety
  • For optional adaptive neurostimulation: nonremovable metal in or around the head, known increased intracranial pressure due to infarcts or trauma, professional metal work or prior ocular metal injury, history of rTMS or ECT, or current (es)ketamine treatment
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
140 participants (estimated)

Study arms

  • Experimental
    Personalized pharmaco-lifestyle intervention

    Participants receive one or more individualized intervention modules selected according to predefined eligibility criteria, digital guidance, and shared decision-making. Modules may include exercise, anti-inflammatory diet, sleep intervention, social prescribing, semaglutide, and optional closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms. Weekly guided support is provided through Month 3, followed by self-directed continuation with digital support through Month 6.

    Drug: Semaglutide (SEMA) · Behavioral: Exercise module · Behavioral: Anti-inflammatory diet module · Behavioral: Sleep intervention module · Behavioral: Social prescribing module · Device: Closed-loop transcranial alternating current stimulation (CL-tACS)

  • Active comparator
    Structured lifestyle psychoeducation control

    Participants receive structured psychoeducation and counseling on exercise, diet, sleep, and social contact approximately every four weeks through Month 3, followed by self-guided continuation through Month 6. Participants with prominent depressive symptoms may receive sham closed-loop transcranial alternating current stimulation.

    Behavioral: Structured lifestyle psychoeducation · Device: Sham CL-tACS

Interventions

  • DrugSemaglutideStudies of SemaglutideSemaglutide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Once-weekly subcutaneous semaglutide for eligible participants with overweight or obesity and metabolic risk, titrated according to protocol up to 2.4 mg/week as tolerated, followed by tapering after Month 6.

  • BehavioralExercise module

    Personalized moderate-intensity exercise intervention with supervised sessions during the structured phase and supported maintenance, targeting at least 150 minutes of moderate physical activity per week.

  • BehavioralAnti-inflammatory diet module

    Structured anti-inflammatory dietary intervention based on the Brain Anti-Inflammatory Nutrition (BrAIN) diet, supported by coaching, recipes, and digital materials.

  • BehavioralSleep intervention module

    Adapted cognitive behavioral therapy for insomnia (SLEEPexpert) including a structured introduction and supported self-management.

  • BehavioralSocial prescribing module

    Structured intervention to increase social participation, community engagement, and behavioral activation.

  • DeviceClosed-loop transcranial alternating current stimulation (CL-tACS)

    Optional adjunctive bifrontal closed-loop transcranial alternating current stimulation for participants with prominent depressive symptoms.

  • BehavioralStructured lifestyle psychoeducation

    Control intervention consisting of psychoeducation and counseling on lifestyle domains with self-guided continuation.

  • DeviceSham CL-tACS

    Sham closed-loop transcranial alternating current stimulation in the control arm for eligible participants with prominent depressive symptoms.

06

What researchers measure

Primary outcomes

  1. Change in Short Form 36 Health Survey (SF-36) Mental Component Summary (MCS) score

    Change from baseline in the SF-36 Mental Component Summary score.

    Time frame: Baseline to Month 3

Secondary outcomes

  1. Change in Short Form 36 Health Survey (SF-36) Mental Component Summary score (MCS) at Month 6

    Time frame: Baseline to Month 6

  2. Change in Short Form 36 Health Survey (SF-36) Physical Component Summary (PCS) score

    Time frame: Baseline to Month 3 and Month 6

  3. Change in Short Form 36 Health Survey (SF-36) total score

    Time frame: Baseline to Month 3 and Month 6

  4. Change in MATRICS Consensus Cognitive Battery

    Time frame: Baseline to Month 3 and Month 6

  5. Change in Insomnia Severity Index (ISI)

    Time frame: Baseline to Month 3 and Month 6

  6. Change in UCLA Loneliness Scale score

    Time frame: Baseline to Month 3 and Month 6

  7. Change in International Physical Activity Questionnaire

    Time frame: Baseline to Month 3 and Month 6

  8. Change in EQ-5D-3L score

    Time frame: Baseline to Month 3 and Month 6

  9. Incidence of adverse events and serious adverse events

    Time frame: Baseline through day 240-243

  10. Change in Brief Psychiatric Rating Scale (BPRS) psychotic symptoms

    Time frame: Baseline to Month 3 and Month 6

  11. Change in Montgomery-Åsberg Depression Rating Scale (MADRS)

    Time frame: Baseline to Month 3 and Month 6

  12. Change in Young Mania Rating Scale (YMRS)

    Time frame: Baseline to Month 3 and Month 6

  13. Change in Pittsburgh Sleep Quality Index (PSQI) scores

    Time frame: Baseline to Month 3 and Month 6

  14. Change in step aerobic test performance

    Time frame: Baseline to Month 3 and Month 6

  15. Change in grip strength

    Time frame: Baseline to Month 3 and Month 6

  16. Change in body weight

    Time frame: Baseline to Month 3 and Month 6

  17. Change in body mass index (BMI)

    Weight and height will be combined to report BMI in kg/m\^2

    Time frame: Baseline to Month 3 and Month 6

  18. Change in waist-to-hip ratio

    Time frame: Baseline to Month 3 and Month 6

  19. Chage in blood pressure

    Time frame: Baseline to Month 3 and Month 6

  20. Change in lean mass

    Time frame: Baseline to Month 3 and Month 6

  21. Change in fat mass

    Time frame: Baseline to Month 3 and Month 6

07

Study locations

5 sites
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2028; primary completion for Jul 2030, 21 months later.

Of 668 non-industry interventional studies with no phase under Mental Disorders, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 45. This study's planned 21 months is below that.

Counting every sponsor, half of 682 studies reached it within 29 months; a quarter within 13 and three quarters within 45.

Mental Disorders covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2026
First posted
May 14, 2026
StartEst.
Oct 2028
Primary completionEst.
Jul 2030
CompletionEst.
Dec 2030
Last update
May 14, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 14, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07586150
Responsible party
Isabel Maurus (Senior Consultant, Department of Psychiatry and Psychotherapy, LMU University Hospital, Ludwig-Maximilians - University of Munich) — Principal investigator
First posted
May 14, 2026
Start date
Oct 2028 (estimated)
Primary completion
Jul 2030 (estimated)
Completion
Dec 2030 (estimated)
Last update
May 14, 2026

Study contacts

Peter Falkai, MD
Contact
peter.falkai@med.uni-muenchen.de
+49 89 4400 - 55501

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Semaglutide

Start the discussion